A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

Part of paid clinical trials in San Francisco, California.

Sponsor
MiNK Therapeutics
Study ID
NCT07615010
Phase
PHASE2
Status
Recruiting

Conditions

  • Pneumonia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • agenT-797 — DRUG
    Intravenous infusion
  • Placebo — DRUG
    Intravenous infusion
  • Standard of Care (SOC) — DRUG
    Antimicrobial therapy and corticosteroids per applicable guidelines.

Study Details

This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).

Key Dates

Start date
May 22, 2026
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: agenT-797 plus SOC
    Participants will receive agenT-797 and SOC.
  • Placebo Comparator: Placebo plus SOC
    Participants will receive placebo and SOC.

Primary Outcome Measure

Number of Deaths (All-cause Mortality) [ Time Frame: Day 1 through Day 28 ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
UCSF Medical Center at Parnassus HeightsSan FranciscoCalifornia94143
Michael Matthay, MD (PRINCIPAL_INVESTIGATOR)
Children's Memorial Hermann HospitalHoustonTexas77030
Charles Cox, MD (PRINCIPAL_INVESTIGATOR)
University HospitalSan AntonioTexas78229
Donald Jenkins, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

Related Studies